Bacil Pharma Limited (BOM:524516)
India flag India · Delayed Price · Currency is INR
36.90
0.00 (0.00%)
At close: Aug 25, 2025

Bacil Pharma Income Statement

Millions INR. Fiscal year is Apr - Mar.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 20212017 - 2021
Period Ending
Jun '25 Mar '25 Mar '24 Mar '23 Mar '22 Mar '21 2017 - 2021
Selling, General & Admin
1.441.380.990.860.60.52
Upgrade
Other Operating Expenses
1.741.150.880.910.951.09
Upgrade
Operating Expenses
3.182.541.891.81.591.67
Upgrade
Operating Income
-3.18-2.54-1.89-1.8-1.59-1.67
Upgrade
Interest Expense
---0.01-0.01-0.01-0.05
Upgrade
Interest & Investment Income
--0.30.290.580.74
Upgrade
Other Non Operating Income (Expenses)
16.536.61----
Upgrade
EBT Excluding Unusual Items
13.354.08-1.6-1.52-1.02-0.97
Upgrade
Gain (Loss) on Sale of Investments
--1.010.5-0.63-1.42
Upgrade
Gain (Loss) on Sale of Assets
-----36.95-
Upgrade
Pretax Income
13.354.08-0.59-1.02-38.6-2.4
Upgrade
Income Tax Expense
2.280.030-0-0-0
Upgrade
Net Income
11.074.04-0.59-1.02-38.6-2.39
Upgrade
Net Income to Common
11.074.04-0.59-1.02-38.6-2.39
Upgrade
Shares Outstanding (Basic)
866666
Upgrade
Shares Outstanding (Diluted)
866666
Upgrade
Shares Change (YoY)
34.82%-0.82%-1.48%1.71%0.99%-0.04%
Upgrade
EPS (Basic)
1.400.69-0.10-0.17-6.55-0.41
Upgrade
EPS (Diluted)
1.400.69-0.10-0.17-6.55-0.41
Upgrade
Free Cash Flow
-4.01-0.03-1.48-40.09-3.98
Upgrade
Free Cash Flow Per Share
-0.68-0.01-0.25-6.80-0.68
Upgrade
EBITDA
-3.18-2.53-1.87-1.77-1.55-1.62
Upgrade
D&A For EBITDA
00.010.020.030.040.05
Upgrade
EBIT
-3.18-2.54-1.89-1.8-1.59-1.67
Upgrade
Effective Tax Rate
17.10%0.83%----
Upgrade
Revenue as Reported
16.536.611.311.150.580.74
Upgrade
Source: S&P Global Market Intelligence. Standard template. Financial Sources.